Ann: Mining Licence Update, page-127

First 127 Last

Share
Profile

Follow
iamagenius

6,574 Posts.

472

18/07/22

14:53

Post #: 62590303
Share

Originally posted by Mining8: ↑

Response to Sector:

T.O.T.A.L. R.U.B.B.I.S.H.!

AVZ has the largest hard rock resource globally([email protected]%Li2O); thus they are planning to produce a 10 Mtpa output.

This is over twice the size of PLS's two plant outputs combined, then add the value of AVZ's primary lithium sulphate(value added) and tin.(3rd largest tin resource globally) The NPV will be A.S.T.R.O.N.O.M.I.C.A.L.! And when you compare AVZ to PLS with a similar amount of shares on issue, the fact that PLS cannot economically produce battery grade(SC 5.5 and not SC 6.0-AVZ) AVZ is W.A.Y. W.A.Y. U.N.D.E.R.V.A.L.U.E.D.!

Also the spodumene price used in its original DFS was $600. It is now over 10 times that figure. This will also have a huge multiplier affect on the value of AVZ when the BFS is released which will be after the mining licence and funding.

So the value of AVZ will be enormous; both current and projected because AVZ has the potential to output 40 Mtpa when you look at its exploration target of 1.5 billion tonnes that Managing Director Nigel Ferguson thinks can be obtained easily.

Also coming out of suspension with the full mining licence and funding(CATH)(CATL) are huge positive de-risking catalysts to the market!

Exciting times ahead for AVZ holders!

AIMO

Expand

Do u know pls has no sovereign risk , do you know pls is 100% owned , do you know pls is in production and debt free , do u know
Pls will have over $2b cash this fy

what does AVZ have besides a African handshake ? Or is it the Congo wink

AVZ Price at posting: 78.0¢ Sentiment: None Disclosure: Not Held
12 Upvote

3 Great analysis

Reply

Top Stories

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Good habits matters when it comes to finances

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN